| Document |
Document Title |
|
JP4598771B2 |
The present invention relates to the area of blood clotting. The invention relates in particular to certain heterocyclic compounds, to processes for their preparation, to their use for the treatment and/or prophylaxis of diseases, and to...
|
|
JP4544857B2 |
The present invention provides novel compounds represented by formula I or pharmaceutically acceptable salts thereof useful for treating flaviviridae viral infection.
|
|
JPWO2008149965A1 |
As a result of diligent studies on EP4 receptor agonists, the inventors have substituted the 1-position of the pyridone ring with a group having an acidic group such as a carboxyl group, and the 6-position is a lower alkyl, lower alkylen...
|
|
JP4522850B2 |
The invention relates to 3-pyridylcarboxamide derivatives of formula (I): wherein the various symbols are as defined in the description, compositions thereof, methods for controlling pests by applying same, and processes for their prepar...
|
|
JP4518956B2 |
Novel oxazole and thiazole compounds, including derivatives thereof, to intermediates for their preparation, to pharmaceutical compositions containing them and to their medicinal use are described. The compounds of the present invention ...
|
|
JPWO2008123207A1 |
To provide a compound useful as a therapeutic agent for chronic renal failure and a therapeutic agent for diabetic nephropathy. As a result of diligent studies on an ornithine derivative having an EP4 receptor antagonism, the inventors h...
|
|
JP4503724B2 |
|
|
JP4490421B2 |
The present invention provides a method for the treatment of schizophrenia which comprises administering a compound of formula wherein the substituents are as described herein or a pharmaceutically active acid-addition salt thereof. In p...
|
|
JP2010507640A |
The invention relates to a novel group of compounds of Formula (I) or a salt thereof: wherein R1, A and HET-1 are as described in the specification, which may be useful in the treatment or prevention of a disease or medical condition med...
|
|
JP4430749B2 |
4-Sulphonamido-benzopyran derivatives (I) are new. 4-Sulphonamido-benzopyran derivatives of formula (I) and their salts are new: R<1>, R<2> = H, CF3, C2F5, C3F7, alkyl, or phenyl optionally mono- or disubstituted; or R<1> + R<2> = alkyle...
|
|
JP2010503671A |
The present application describes organic compounds that are useful for the treatment, prevention and/or amelioration of human diseases.
|
|
JP2009542673A |
The present invention relates to certain biphenyl sulfonamide derivatives of Formula (Ia) and pharmaceutical compositions thereof that modulate the activity of the histamine H3-receptor. Compounds and pharmaceutical compositions thereof ...
|
|
JP4306805B2 |
Benzoyl derivatives of the formula I where the variables have the following meanings: R1, R2 are hydrogen, nitro, halogen, cyano, alkyl, haloalkyl, alkoxy, haloalkoxy, alkylthio, haloalkylthio, alkylsulfinyl, haloalkylsulfinyl, alkylsulf...
|
|
JPWO2007105637A1 |
Since the compound represented by the general formula (I), its salt, its N-oxide form, their solvate, or their prodrug specifically binds to CCR5, CCR5-mediated diseases such as various types Inflammatory diseases (asthma, nephritis, nep...
|
|
JP4276280B2 |
Disclosed is a compound useful as a type I 11²hydroxysteroid dehydrogenase inhibitor. A compound represented by the formula: a pharmaceutically acceptable salt or solvate thereof, wherein R 1 is optionally substituted alkyl or the like,...
|
|
JP4274795B2 |
The invention relates to novel N-phenyl-4-(4-pyridyl)-2-pyrimidineamine derivatives of the general formula (I) wherein the sum of (m+p) together is 0, 1, 2 or 3; n and q are independently of each other 0 or 1, and the sum of (m+p+q) toge...
|
|
JP4259620B2 |
4-(3-Heterocyclyl-benzoyl)-pyrazole derivatives (I) and their salts are new: R1, R3 = H; NO2; halo; CN; 1-6C alkyl, 1-6C alkoxy, 1-6C alkylthio, 1-6C alkylsulphinyl or 1-6C alkylsulphonyl optionally substituted by halo; H2NSO2; (1-6C alk...
|
|
JP2008545684A |
Compounds of formula (I), wherein R1, R4, HET-1 and HET-2 are as described in the specification, and their salts and pro-drugs, are activators of glucokinase (GLK) and are thereby useful in the treatment of, for example, type 2 diabetes....
|
|
JP2008540418A |
This invention relates to inhibitors of mitotic kinesins, particularly KSP, and methods for producing these inhibitors. The invention also provides pharmaceutical compositions comprising the inhibitors of the invention and methods of uti...
|
|
JP4167731B2 |
derivs. of formula (I) are new: R = H, halogen, 1-4C alkyl, 1-4C haloalkyl, 1-4C alkoxy or 1-4C haloalkoxy; R1 = halogen, X1R2 or R2; X = S; X1 = O or S; R2 = H; 1-4C alky, 3-7C cycloalkyl, 2-6C alkenyl, 4-7C cycloalkenyl or 2-6C alkynyl...
|
|
JP4138489B2 |
Novel compounds of the general formula:and pharmaceutically acceptable acid addition salts thereof, wherein the compounds are useful in therapy to protect skeletal muscles against damage resulting from trauma or to protect skeletal muscl...
|
|
JP2008526912A |
Macrocyclic compounds of the formula in which R1, R3, V1, V2, X1, X2, Y, Z, Ar, AA and n are as defined in the specification, the number of ring atoms included in the macrocyclic ring being 14, 15, 16, 17 or 18, in free base form or in a...
|
|
JP4109271B2 |
The invention provides compounds and pharmaceutically acceptable salts of Formula I wherein the variables A1, A2, R1, R2, V, W, X, Y, and Z are defined herein. Certain compounds of Formula I described herein which possess potent antivira...
|
|
JP4074509B2 |
The present invention relates to methods and intermediates for preparing compounds of the formula 1 and the pharmaceutically acceptable salts and solvates thereof, as well as structurally related compounds, wherein R<1>, R<2> and R<15> a...
|
|
JP4036244B2 |
Compounds are provided which inhibit microsomal triglyceride transfer protein and thus are useful for lowering serum lipids and treating atherosclerosis and related diseases. The compounds have the structure defined herein.
|
|
JP4031705B2 |
The present invention relates generally to a process for recovering copper and other metal values from metal-containing materials using controlled, super-fine grinding and medium temperature pressure leaching. Processes embodying aspects...
|
|
JP2007537180A |
The present invention relates to new substituted thiophene-2-carboxylic acid amides of general formula wherein A, and R1 to R8c are defined as in claim 1, the tautomers, the enantiomers, the diastereomers, the mixtures thereof and the sa...
|
|
JP2007535497A |
The present invention relates to compounds of the formula I, in which R<0> ; R<1> ; R<2> ; R<3> ; R<4>; R<5>, R<6>, Q; V, G and M have the meanings indicated in the claims. The compounds of the formula I are valuable pharmacologically ac...
|
|
JP2007314890A |
To provide an effective method for efficiently recovering copper from a copper-containing substance (particularly copper from a copper sulfide such as chalcopyrite and chalcocite), which realizes a high copper recovery rate at a reduced ...
|
|
JP2007535421A |
One or more reflective layers may optionally be pre-coated with a preferably transparent substrate, the surface of which comprises a light-writable information layer comprising a light-absorbing compound and optionally a binder, and opti...
|
|
JP2007530694A |
A spray head for attachment to an aerosol container containing pressurized product is provided, the spray head comprising conduit means, more than one separate spray outlet and a splitting chamber for diverting the flow to the spray outl...
|
|
JP2007528400A |
The invention relates to novel compounds and also to methods of treating at least one disease, disorder, or condition associated with amyloidosis using such compounds. Amyloidosis refers to a collection of diseases, disorders, and condit...
|
|
JP2007524682A |
The present invention is directed to novel amides such as those of Formula (I): (I) which are mGluR5 modulators useful in the treatment or prevention of diseases and conditions in which mGluR5 is involved, including but not limited to ps...
|
|
JP3967401B2 |
To obtain the subject compound having lower toxicity and esp. wider bactericidal action on Gram-positive coccus, Mycobacteria, Corynebacteria, Haemophilus, Haemophilus and/or Bacillus influenzae and anaerobes. This compound, or its salt,...
|
|
JPWO2005097782A1 |
For example, the following general formula (I) (in the formula, -C (= O)) having an N-methyl-D-asparaginate (NMDA) type glutamate receptor (NR2B / NMDA receptor) antagonism containing an NR2B subunit and the like. -Z is -C (= O) -CH2-, -...
|
|
JP2007516955A |
The present invention relates to a method for treatments relating to bipolar disorder in a mammal, including a human, the treatments including treatment of rapid-cycling bipolar disorder, treatment of symptoms of bipolar disorder selecte...
|
|
JP2007516982A |
The present invention provides a compound having aggrecanase inhibitory activity and MMP-13 inhibitory activity, and useful as a therapeutic agent for osteoarthritis, rheumatoid arthritis and the like, more specifically, a cyclopropane c...
|
|
JP3930560B2 |
A class of imidazolyl compounds is described for use in treating inflammation and inflammation-related disorders. Compounds of particular interest are defined by Formula I: (I) wherein R1-R6 are as described in the specification; or a ph...
|
|
JP3926868B2 |
To obtain a new sulfonamide-substituted benzopyran derivative having potassium channel stimulating activity, useful as a cardiovascular agent, etc. This compound is shown by formula I [R1 is a group of formula II (R8 is an aryl, etc.; R9...
|
|
JP2007512297A |
A phenothiazinium compound of Formula (I) for use as an antimicrobial agent for the prevention of microbial infections wherein: Rl, R2, R3 and R4 each independently is an optionally substituted linear, branched or cyclic hydrocarbon grou...
|
|
JP2006528171A |
The present invention relates the use of antagonists of vasopressin V1a receptors for the treatment of male sexual dysfunction, in particular ejaculatory disorders, such as premature ejaculation or rapid ejaculation. The present inventio...
|
|
JP2006520794A |
The present invention relates to aminopyrazine derivatives, compositions and medicaments containing the same, as well as processes for the preparation and use of such compounds, compositions and medicaments. Such aminopyrazine derivative...
|
|
JP2006225394A |
To provide aryl thiourea derivatives and related compounds which are useful as antiviral agents.Compounds of formula I and pharmaceutically acceptable salts there of: wherein 1-(4-(pentyloxy) phenyl)-3-(4-phenylbutanoyl) thiourea is spec...
|
|
JP2006182648A |
To provide a strong platelet aggregation inhibitor not inhibiting COX-1 and COX-2.The present invention provides a compound represented by general formula (I) or its salt or a solvate thereof and a medicine comprising the compound or its...
|
|
JP2006516572A |
The present invention relates to certain 1,2,3-trisubstituted aryl and heteroaryl derivatives of Formula (Ia) that are modulators of metabolism. Accordingly, compounds of the present invention are useful in the prophylaxis or treatment o...
|
|
JP3743520B2 |
Thienyl-, furyl- and pyrrolyl-sulfonamides, formulations of pharmaceutically acceptable salts thereof and methods for modulating or altering the activity of the endothelin family of peptides are provided. In particular, N-(isoxazolyl)thi...
|
|
JP3741441B2 |
Processes for preparing endothelin antagonists of formula (I) and pharmaceutically acceptable salts thereof and processes for preparing intermediates thereof.
|
|
JP2006017737A |
To develop a therapeutic compound to regulate selectively an immune response, and to treat a T-cell mediated disease.The present invention relates to the discovery that a certain adverse inflammatory response, an allergic disease, an und...
|
|
JP2006501199A |
The present invention is directed to compositions and methods for the treatment of patients with cephalotaxines, for example, homoharringtonine. The invention is also directed to improvements in the purity, manufacturing process, formula...
|
|
JPWO2004026292A1 |
Equation (I)(A indicates an alkoxycarbonylalkyl group, etc., R indicates a hydroxyl group which may be protected, or A and R together form a 6- or 7-membered ring containing an oxygen atom, and B indicates a carbonyl. Indicates a group o...
|
